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Abstract
Advances in the diagnosis and multi-modality treatment of cancer have increased survival rates for many cancer
types leading to an increasing load of long-term sequelae of therapy, including that of cognitive dysfunction. The
cytotoxic nature of chemotherapeutic agents may also reduce neurogenesis, a key component of the physiology of
memory and cognition, with ramifications for the patient’s mood and other cognition disorders. Similarly
radiotherapy employed as a therapeutic or prophylactic tool in the treatment of primary or metastatic disease may
significantly affect cognition. A number of emerging pharmacotherapies are under investigation for the treatment
of cognitive dysfunction experienced by cancer patients. Recent data from clinical trials is reviewed involving the
stimulants modafinil and methylphenidate, mood stabiliser lithium, anti-Alzheimer’s drugs memantine and
donepezil, as well as other agents which are currently being explored within dementia, animal, and cell culture
models to evaluate their use in treating cognitive dysfunction.
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Introduction
Cognitive dysfunction in cancer patients
The possibility that chemotherapy could induce cogni-
tive changes became a focus of research after breast can-
cer patients began to complain of a vague mental
‘fogginess’ that developed during their treatment. This
later came to be defined with the unfortunate term ‘che-
mobrain’ [1-7]. The word chemobrain is now used to de-
scribe a constellation of symptoms across a variety of
cognitive domains, with the most commonly reported
problems being in areas of short-term memory, concen-
tration and attention, and planning [4]. The term che-
mobrain is somewhat of a misnomer, as cognitive
complaints may be seen in a subset of patients prior to
receiving any treatment [1-6,8]. It has become increas-
ingly clear that this pre-treatment dysfunction may be
encountered across different tumour types.
The cognitive domains which are most affected by
chemotherapy or the cancer itself vary according to
study design and testing method. With regards to pa-
tients with breast cancer Wefel et al. found processing
speed, attention, nonverbal memory, executive function,
and problem solving to be the most vulnerable to the ef-
fects of chemotherapy [5,9]. Correa and Hess (2012)
similarly documented deficiencies in executive function,
memory, and reaction time in patients with ovarian can-
cer [10]. Patients who have been treated for primary
brain tumours also display a similar set of cognitive de-
fects to those aforementioned during long term follow
up, with decreased attention, difficulty with expressive
language, executive function, processing speed, and poor
short-term memory seen among survivors of primary
brain tumours [11,12]. Within the paediatric population
it is generally accepted that underlying defects in atten-
tion and/or working memory following treatment for
acute lymphoblastic leukaemia (ALL) or childhood brain
tumours mediate the observed declines in intelligence
quotient (IQ) and academic achievement seen during
longitudinal follow-up [13,14]. The deficiencies seen
mirror those found in children with attention deficit
hyperactivity disorder (ADHD), particularly those symp-
toms of the primary inattentive type of ADHD [15]. This
association has led researchers to trial methylphenidate
in children who display these cognitive defects after
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treatment to determine whether a similar response pro-
file could be obtained [15,16]. This and other trials
involving methylphenidate will be discussed later in this
review.
Largely due to variations in study and testing design
and differing definitions of impairment, there is a large
variation in reported rates of cognitive impairment fol-
lowing treatment. Reported figures range from 15-90%
of patients, and even higher figures have been reported
from patients with brain tumours [7,9,17].
There are challenges in unravelling the cause of cogni-
tive dysfunction in patients with cancer. The changes
caused can often be confused or confounded by other
issues seen in cancer treatment including anxiety, de-
pression, sleep disturbance, or fatigue [1,7,18]. Increased
levels of circulating cytokines have been implicated in
mediating some of these changes, especially so in the
case of pre-treatment cognitive dysfunction [19].
Defining exactly what changes chemotherapy induces
has remained elusive. One proposed mechanism is
chemotherapy-induced de-oxyribonucleic acid (DNA)
damage, either directly or indirectly through oxidative
stress. Chemotherapy may also induce hormonal changes,
an immunologic-driven process, microvascular injury, and/
or decreased neurogenesis [9,20].
Cranial irradiation can also induce pathological
changes that have been described as similar to the dis-
ease process in Alzheimer’s Disease [7,21]. Radiation-
induced neurocognitive changes are often seen early in
the post-radiotherapy period, and more subtle changes
may also be observed several years later in patients
who are long-term survivors [22].
Glucocorticoids, the use of which is highly prevalent
in patients with cancer, have been associated with a 5–
50% incidence of glucocorticoid-induced psychiatric
syndromes including mania, insomnia, restlessness, eu-
phoria, and increased motor activity [5]. The use of opi-
oids can produce drowsiness and decreased cognitive
function [23]. In the late stages of treatment and particu-
larly in the palliative care setting, opioid-induced delir-
ium can be observed, however, delirium in this setting is
often multi-factorial [7]. It is well known that metho-
trexate and 5-fluorouracil are directly neurotoxic and
can cause diffuse white matter changes, and agents such
as doxorubicin, paclitaxel, cisplatin, and cyclophospha-
mide are also implicated [9].
Factors that increase one’s risk of developing neuro-
toxicity related to chemotherapy include: the use of
high-dose regimens or exposure to high doses of the
parent drug or its metabolite due to impaired systemic
clearance or pharmacologic modification of hepatic en-
zyme systems; synergistic effects of different chemother-
apeutic agents; the synergistic effect of multi-modality
treatment, which includes radiotherapy; agents that can
cross or processes that disrupt the blood–brain barrier
(BBB); and intrathecal administration of cytotoxic che-
micals [9].
Dysfunction induced by therapy also appears to be
related to the intensity of therapy. Studies performed in
patients with breast cancer have shown that the relative
risk of cognitive dysfunction is 3·5 times higher in pa-
tients who received intensive regimes of chemotherapy
(cyclophosphamide, high-dose thiotepa-carboplatin)
compared to patients who were treated with cyclo-
phosphamide alone [24].
Significant numbers of cancer patients suffer cognitive
impairments and concurrent mood disorders which may
impact on their functional ability. This may be due to
cancer within the Central Nervous System (CNS), para-
neoplastic effects and the various treatments modalities
offered. This paper offers a review of the emerging phar-
macotherapies, which attempt to prevent or minimise
cognitive dysfunction in these settings.
Review
Pharmacotherapy for cancer patients with cognitive
dysfunction
Modafinil
Modafinil is a novel stimulant that currently has United
States (US) Food and Drug Administration (FDA) au-
thority for use in narcolepsy [25]. The exact mechanism
of action for modafinil remains largely unknown. It has
been demonstrated that in a similar fashion to deriva-
tives of amphetamine modafinil is able to increase
catecholaminergic signalling. However in contrast to the
amphetamine derivatives, which act broadly throughout
the cortex and striatum to produce excitation, modafinil
has been shown to act primarily within sleep-wake
centres in the anterior hypothalamus to promote wake-
fulness [26,27]. It is believed to do this through inhib-
ition of gamma-amino butyric acid (GABA) outflow
from the sleep-generating ventrolateral pre-optic area of
the hypothalamus [28]. Modafinil has not been shown to
stimulate dopaminergic transmission throughout the
cortex or produce significant sympathomimetic side
effects [28]. This selective action on thalamic sleep-wake
centres is thought to be the reason that modafinil
displays a lower side effect profile as compared to
methylphenidate in addition to having a lower abuse
potential [26-28].
Whilst many clinical trials have looked at the effects of
modafinil on fatigue within cancer patients, there have
been comparatively few which have looked primarily at
cognitive dysfunction. Kohli et al. (2009) looked at the
effect of modafinil on cognitive dysfunction as a second-
ary analysis of a previous trial which looked at its effi-
cacy in the treatment of cancer related fatigue. In an
open-label Phase I/ II study, 82 women with an initial
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diagnosis of breast cancer who had been treated with
chemotherapy and/or radiation therapy one month prior
to the study were assessed. Patients had previously been
enrolled within a primary study conducted by the au-
thors which looked at the effects of modafinil on self-
reported fatigue on the basis of a score of greater than
two on the Brief Fatigue Inventory (BFI) [29] and only
those patients who had given a score of 2 (indicating
worst fatigue) were invited to participate. In Phase I of
the current study, patients received 200mg of modafinil
once daily for four weeks, and those who had favourable
responses were then randomised to modafinil or placebo
for an additional four weeks in Phase II. Cognitive Drug
Research (CDR) computerised testing was used as a bat-
tery at baseline. After completion of both phases, moda-
finil was found to demonstrate significant improvement
in speed of memory and episodic memory within the
open label phase I, and those who were assigned modafi-
nil within the placebo controlled phase II continued to
show improvement in those domains when compared to
women who were randomised to receive placebo. As
such the authors concluded that modafinil might be
useful in enhancing memory and attention skills.
Lundorff et al. (2009) in a double blind, randomised
cross over trial looked at the effect of modafinil against
placebo on cognitive function as a primary outcome
with secondary aims of looking at the effectiveness of
modafinil on other symptoms. 28 patients with advanced
cancer in a palliative care setting who had a self-
reported tiredness score of five or more (range 0–10,
where 0 was no tiredness and 10 was the worst possible
tiredness) and a Karnofsky Performance Status of 40–70
were invited to participate. On day one patients ran-
domly received 200 mg of modafinil or placebo before
being switched to the alternative treatment on day four
[30]. The Trial Making Tests A and B, Finger Tapping
Test (FTT), and Edmonton Symptom Assessment
System (ESAS) were performed at baseline and then four
hours after the tablets were taken. The authors showed a
statistical improvement on modafinil in all three tests of
cognitive function compared to placebo and additionally
reported that subjective scores of depression and drowsi-
ness were improved in those who had been treated with
modafinil.
Blackhall et al. (2009) performed a pilot study which
looked primarily at the effect of modafinil on cancer-
related fatigue and secondarily on outcomes of cognitive
function [31]. 27 patients with a variety of different can-
cers were recruited. Modafinil was given at 100 mg daily
for two weeks, then 200 mg for a further two weeks.
Assessment of cognitive function in the study was done
using the Hopkins Verbal Learning Test (HVLT), the
Grooved Pegboard Test, the Controlled Oral Word As-
sociation Test (COWAT) and the Trail Making Test A
was performed at baseline, after two weeks and after
four weeks of treatment with modafinil. The authors
found that in comparison to the positive effects on fa-
tigue and self-reported quality of life in their primary
outcomes, modafinil was not associated with significant
improvement in measures of cognitive function.
Methylphenidate
Methylphenidate has been far more extensively studied
in relation to cognitive dysfunction amongst cancer pa-
tients that the other stimulants reviewed here, particu-
larly in the paediatric population. Methylphenidate acts
in a similar fashion to amphetamines. It is a dopamin-
ergic and noradrenergic agonist that increases concen-
trations of these neurotransmitters in the fronto-striatal,
network (the network which governs attention) [32,33].
It also reduces dopamine uptake at synapses and has
been shown to inhibit the action of monoamine oxidase
[33]. Owing to the ability of methylphenidate to induce
widespread cortical activation it is also associated with
more significant side effects than modafinil. The most
troublesome of methylphenidate’s side effects include;
appetite suppression, anxiety, restlessness, sweating, hal-
lucinations, tolerance, and addictive properties [34].
Mar Fan et al. (2008) in a randomised, placebo-
controlled double-blind trial studied the effects of me-
thylphenidate on both cognitive function and fatigue in
women undergoing adjuvant chemotherapy for fully
resected early breast cancer. The authors looked at 57
women who initially randomised to 5 mg twice daily of
placebo run in [35]. Those patients who were compli-
ant with medication and the testing battery were then
randomised to either 5 mg of methylphenidate twice
daily or placebo. Patients were assessed at baseline,
at the end of their chemotherapy cycles, and after six
months with the Mini-Mental State Examination
(MMSE), High Sensitivity Cognitive Screen (HSCS)
and the Hopkins Verbal Learning Test-Revised (HVLT-R).
The authors found no statistically significant difference
in cognitive function between methylphenidate or pla-
cebo on HVLT-R or HSCS scores at the conclusion of
their trial.
Lower et al. (2009) in a randomised, placebo-controlled
double-blind study looked at the effects of methylphenidate
primarily on fatigue with secondary measures of cognitive
function [36]. One hundred and fifty-four patients with pre-
dominantly breast or ovarian cancer who had previously
completed initial cycles of treatment greater than 2 months
before study initiation. Measures of cognitive function were
done with the HSCS. Whilst the authors found no signifi-
cant improvement in cognitive function as measured by the
HSCS at the conclusion of the study period, they noted that
their study was not powered to fully assess such a
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secondary endpoint and regarded such an outcome as ex-
ploratory only.
Gagnon et al. (2005) performed a prospective clinical
study which looked at the efficacy of methylphenidate in
cancer patients who were also suffering from hypoactive
delirium. A total of 14 patients with hypoactive delirium
were included in the study. Patients were given 10mg of
methylphenidate twice daily and were asked to perform
an MMSE one hour after the administration of methyl-
phenidate on each follow-up visit, daily for inpatients,
every three to four days for outpatients [23]. Improve-
ment from the baseline MMSE score of 21 out of 30 was
noted in all patients following treatment, with the me-
dian score improving to 28. The authors concluded that
the use of methylphenidate was the reason for their pa-
tients’ rather surprising improvement in MMSE scores.
Gehrig et al. (2012) performed a small, open-label ran-
domised pilot trial which directly compared both imme-
diate release and long acting forms of methylphenidate
against modafinil. A total of 24 patients with the diagno-
sis of a primary brain tumour who subjectively com-
plained of cognitive dysfunction were recruited into the
trial [37]. Patients were asked to complete several
psychometric tests which included; HVLT-R, COWAT,
trail making tests A and B, and the Abbreviated Wechs-
ler Intelligence Scale for Children (WAIS-III) digit span
and digit symbol tests at baseline and again at four
weeks. However due to slow accrual the trial was termi-
nated early. Whilst there was suggestion of beneficial
effects on patient-reported measures for both drugs, the
authors advise caution in interpreting the results due to
the small study size.
Methylphenidate has also been studied within paediat-
ric populations who experience cognitive dysfunction,
particularly attention and learning disorders following
treatment for childhood cancers. Conklin et al. (2007)
performed a double-blind cross over trial looking at 122
children who were survivors of either acute lympho-
blastic leukaemia or primary brain tumours. Such pa-
tients had completed treatment regimes a minimum of
12 months prior and were between 6 and 18 years of age
who currently had learning impairments thought to be
a consequence of their treatment regimes [14]. Partici-
pants received either methylphenidate 0.60 mg/kg to a
maximum of 20 mg or placebo and were subsequently
switched to the alternative treatment the following day.
90 minutes after administration participants were asked
to complete; the Brief Continuous Performance Test
(CPT), the California Verbal Learning Test Children’s
Version (CVLT-C), the Visual-Auditory Learning Test
(VAL), the Wide Range Achievement Test (WRAT) and
Barkley’s Side Effects Rating Scales. The authors found
that the domains which showed the most benefit in
those who received methylphenidate were those which
looked at measures of processing speed and response
tendency. Measures of attention did not significantly im-
prove, nor did those which looked at memory encoding/
retrieval or productivity.
Donepezil
Donepezil is a centrally acting anti-cholinergic that is that
is currently used mainly in the treatment of Alzheimer’s
Disease [38]. The major side effects of donepezil relate to
its anti-cholinergic properties, and include; vomiting, diar-
rhoea, and weight loss [11,38]. As hippocampal-related
memory loss is seen as a common side effect of chemother-
apy, it is reasonable to assume that donepezil might have
beneficial effects on cognitive function when used in these
patients [39,40].
Winocur et al. (2011) looked at the effects of donepe-
zil on cognitive impairment in a murine model where
cognitive dysfunction was induced with a combination
of methotrexate and 5-fluorouracil [40]. Four groups of
mice were given: chemotherapy only, chemotherapy and
donepezil, saline only, or saline and donepezil and then
subjected to learning and memory tests within a water
maze. The tests included; a standard spatial memory
test, non-spatial tests of cued memory and tests of
non-matching to sample rule learning and delayed non-
matching to sample. It was found that chemotherapy-
induced cognitive dysfunction was significantly reduced in
the group treated with chemotherapy and donepezil a find-
ing that was so strong their performance results were simi-
lar to the group who had received saline only. The authors
suggested that their study showed that chemotherapy did
induce chronic cognitive changes and that donepezil could
be used to ameliorate some of these changes.
A number of relatively small studies have looked at
the efficacy of donepezil in cancer patients. Castellino
et al. (2012) performed a pilot study of donepezil in 11
children who were survivors of primary brain tumours
who had received greater than or equal to 23·5Gy during
the course of their treatment [11]. Such patients had to
have not received treatment in the past 12 months. The
study was conducted as an open label trial with escal-
ation to the target dose of donepezil by week 6 followed
by a washout period of the drug from weeks 24–36.
Neurocognitive assessment was conducted at baseline
and at weeks 12, 24 and 36 following washout. Assess-
ment was performed with the Dellis-Kaplan Executive
Function (D-KEF), Wide Range Assessment of Memory
and Learning 2nd edition (WRAML-2), CPT, the Wechsler
Intelligence Scale for Children (WISC-IV) and Woodcock
Reading Mastery Test and III Calculations. The authors
found preliminary evidence for the efficacy of donepezil
in the domains of executive function and memory, with
significant performance improvements noted within the
D-KEFs tower task.
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Shaw et al. (2006) performed a prospective, open-label
Phase II study of donepezil in 34 irradiated, mostly low-
grade glioma patients. Such patients had completed
treatment courses 6 months prior to study enrolment
with a Karnofsky Performance Status > 70. Donepezil
was given at 5 mg/d for six weeks, then 10 mg/d for 18
weeks, followed by a 6-week washout period. The cogni-
tive test battery employed the use of the MMSE, Trail
Making Test A and Digit Span Test, the Revised Ray-
Osterrieth Complex Figure Test, Controlled Oral Word
Association Test, CVLT and Trail Making Test B at
baseline and then weeks 6, 12, 24 and 30. Scores signifi-
cantly improved between baseline and week 24 on mea-
sures of attention/concentration, verbal memory and
figural memory. A tend for improvement in verbal flu-
ency was also noted [12].
Lithium
Lithium, a cation that is mainly used in the management
of bipolar mood disorder, is another agent that has been
shown to have both neuroprotective and anti-apoptotic
effects [41]. Epidemiologic studies in patients on long-
term lithium for bipolar disorder suggest that they are
less likely to have cognitive impairment when compared
with similar patients managed on mood stabilisers other
than lithium [42]. Yazlovitskaya et al. looked at the
neuro-protective effects of lithium against cranial irradi-
ation in a murine model. Mice were pre-treated with in-
traperitoneal lithium at 40 or 80 mg/kg for seven days
whilst a control group was given saline at 150 mmol/L.
The animals were then either irradiated with 1–10 Gy of
radiation and sacrificed 10 hours later for histologic
staining, or irradiated with 7 Gy and tested on the
Morris Water Maze 6 weeks later. The authors found
that the pre-treatment of mice with lithium for seven
days before cranial irradiation confers a significant anti-
apoptotic effect, particularly within the hippocampus
where control mice experienced severely altered hippo-
campal function. Such findings have been echoed by
other researchers who have also looked into the poten-
tial protective effects of lithium. Inouye et al. (1995)
pre-treated mice with 10 micromol/g of lithium 2 hours
before irradiation with 0.5 Gy and found that the histo-
logic manifestations were delayed in mice who had been
pre-treated with lithium [43]. Cimarosti et al., looking at
the effects of ischaemia in sections of rat hippocampi
found that the use of lithium in this situation conferred
a neuroprotective effect against the ischaemic state [44].
There has been one early-phase study, presented in ab-
stract form, in which lithium was used as a neuroprotec-
tant [45,46]. Another pilot study using lithium as a
neuroprotectant in Small Cell Lung Cancer Patients
receiving prophylactic cranial irradiation is ongoing.
Efficacy data from a larger study in patients with brain
metastases treated with whole brain radiotherapy are in
planning.
Peroxisome proliferator-activated receptor agonists
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclearhormone receptor superfamily.
Rosiglitazone and Pioglitazone, also called thiazolidine-
dione or glitazones, are used as oral hypoglycemic agents
or insulin sensitisers for the treatment of diabetes.
Glitazones act by activating PPARs with greatest specifi-
city for the PPARγ (gamma) member of the superfamily.
Administering pioglitazone to young adult male rats
starting three days prior to, during, and for four or 54
weeks after the completion of a total 40 Gy dose of
whole brain radiation prevented radiation-induced cog-
nitive dysfunction assessed 52 weeks after the radiation
delivery [47]. An early-phase clinical trial has been initi-
ated to determine the dose of pioglitazone that can be
given safely in this setting.
Angiotensin receptor blockers
Other drugs that have been investigated in animal
models include Angiotensin Receptor Blockers (ARB),
commonly used as antihypertensives, as well as the
chronic administration of angiotensin type 1 (AT1) re-
ceptor antagonist, L-158,809. The latter, when adminis-
tered for three days in rats before, during, and only five
weeks after radiotherapy, prevented cognitive dysfunc-
tion observed 26 weeks post-irradiation [48].
Targeting the nitric oxide pathway
Nitric oxide synthase (NOS) cofactor 5,6,7,8-tetrahydro-
biopterin (BH4) has also been proposed as an agent
to reduce radiation-induced cognitive damage. This is
based on considering BH4 as an essential cofactor for
NOS enzymes. Insufficient BH4 may lead to uncoupling
of the NOS enzyme. In an uncoupled state, NOS can
produce highly oxidative radicals at the cost of NO.
Under conditions of oxidative stress such as after
radiation exposure, BH4 availability might be reduced
because of rapid oxidation. As a result, free radical-
induced BH4 insufficiency may increase the oxidative
burden and hinder the NO-dependent endothelial func-
tion [49].
Memantine
Recently, Brown et al. (2012) reported results of a rando-
mised, placebo-controlled, double-blind trial looked at
the effects of memantine. This agent is a N-methyl
D-aspartate (NMDA) antagonist which has found prior
use in the treatment of Alzheimer’s Disease, in patients
who had received whole brain radiation therapy for
metastatic disease. A total of 508 eligible patients
were randomised to either receive placebo or 20 mg of
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memantine within 3 days of the initiation of radiother-
apy for 24 weeks. Participants were assessed using the
HVLT-R delayed recall, COWAT, and Trail Making Test
1 testing battery at baseline and weeks 8.16, 24 and 52.
The authors showed that there was a significantly lon-
ger time to cognitive decline in those who had been
randomised to receive memantine. In addition, fewer
patients who were on memantine experienced decline
in COWAT or the Trail Making Test A compared to
placebo [50].
Other potential neuroprotective agents
Whilst few of the following agents have been studied for
their beneficial effects in the management of cognitive
dysfunction within cancer patients, research into their
efficacy is an area of growing research within the fields
of mood disorders and dementing illnesses. As such they
are presented with those limitations in mind with the
thought that they may one day be further researched
specifically within a population of cancer and chemo-
therapy induced cognitive impairment.
N-acetyl cysteine
N-acetyl cysteine (NAC) functions as a readily bio-
available source of cysteine, the rate limiting step in the
synthesis of the potent antioxidant glutathione and a
precursor to glutathione, which has been shown to be
one of the most important scavengers of free radicals
within neural tissue [51,52]. It has also been shown to
blunt the inflammatory response within the brain within
a number of conditions, including; multiple sclerosis,
endotoxaemia, ischaemia-reperfusion injury, and hypoxic
ischaemic encephalopathy [53]. In an underpowered
placebo-controlled study in bipolar disorder, no effect on
cognition was noted [personal communication].
While NAC has not been subject to studies within
cancer patients with cognitive dysfunction, it has been
trialled in dementia patients (specifically in those with
Alzheimer’s Disease) and in patients with bipolar mood
disorder [51,52]. In a randomised, double-blind trial of
NAC against placebo in 43 patients who met the diag-
nostic criteria for probable Alzheimer’s Disease, Adair
et al. gave NAC at a dose of 50 mg/kg/d and measured
outcomes using the MMSE at baseline, 12 weeks and 24
weeks. The authors found that active treatment with
NAC failed to significantly alter primary outcome mea-
sures, but did note that a direct comparison of interval
change favoured the NAC group for most outcome mea-
sures although only a few of these were significantly
different [54].
Resveratrol
Interest in resveratrol, a polyphenolic phytoalexin found
within plant sources such as berries, nuts and grapes,
was first aroused by epidemiologic studies that suggested
that subjects who consumed a high proportion of wine
had a lesser incidence of dementia than populations who
did not [55]. It has been suggested that the moderate
consumption of red wine, rich in compounds such as
resveratrol, helps to ameliorate some of the detrimental
cognitive effects seen in dementing illnesses such as Alz-
heimer’s Disease [56,57]. The findings of these studies
have been reinforced by mouse models in which resvera-
trol demonstrated anti-apoptotic, antioxidant and acetyl-
cholinesterase activity controlling properties [56]. While
resveratrol has reached Phase II clinical trials [57], the
applicability of using it within cancer patients remains to
be established. The use of resveratrol and related com-
pounds has certainly been questioned in trials of patients
with Alzheimer’s Disease with randomised trials showing
no cognitive benefit of these drugs. It should be noted
that these trials were of a short duration (<2 years) and
may not have had enough power to detect a statistically
significant difference [57]. Another hypothesis is that the
study of resveratrol and related antioxidants such as cur-
cumin or catechins have been almost exclusively per-
formed in animal models or cell cultures that show little
of the extensive neuronal loss that is seen in patients
with advanced dementia [58]. Therefore, the potential
benefits of antioxidants such as resveratrol remain the
subject of ongoing research.
Non-steroidal anti-inflammatory drugs
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) fall
under the same curious category as resveratrol and
related antioxidants in that, while benefits have been
shown in preventing cognitive decline in epidemiological
and cell culture studies, these benefits have failed to
translate into meaningful clinical results in controlled
trials. The suggestion that NSAIDs might be beneficial
in halting the rate of cognitive decline came from epi-
demiological studies of rheumatology patients taking
regular NSAIDs which again showed a lower incidence
of dementia than other populations [57]. Community-
based prospective studies and some cross-sectional ones
also suggested a benefit to regular aspirin use and
the preservation of global cognitive performance and
episodic memory [59]. Multiple pre-clinical studies in
transgenic mice showed very favourable results in cogni-
tive protection, which suggested a rather straightforward
relationship between the induction of cyclooxygenase
(COX) activity and subsequent prostaglandin-induced
memory dysfunction [60]. However the relationship be-
tween inflammation and cognitive decline proved to be
far more complex than what was originally suggested, as
evidenced by randomised, placebo-controlled trials that
showed no benefit from the traditional NSAIDs nor
from the newer selective COX-2 inhibitors [61].
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Among the NSAIDs, aspirin has received particularly
heavy attention due to its already proven role in the pre-
vention of cardiovascular disease. Aspirin has been sug-
gested to slightly reduce the incidence of mortality from
cancer, as indicated by long-term observational studies
[62]. Kang et al. in a cohort study using data from the
women’s health study, a randomised, placebo-controlled,
double-blind trial with nearly ten years of treatment in
over 6,000 women failed to show any benefit of low-
dose aspirin, with similar cognitive performance after 5.6
years of treatment, 9.6 years and 3–6 years of subse-
quent follow up compared to those who had received a
placebo during that time [63]. A recent Cochrane review
on the use of NSAIDs in slowing the cognitive decline
seen in Alzheimer’s Disease found no significant im-
provement in decline in cognitive function among pa-
tients on aspirin, traditional NSAIDs, selective COX-2
inhibitors, or glucocorticoids, and could not recommend
their routine use in Alzheimer’s Disease [64].
Conclusion
While gains in the understanding of the pathogenesis of
cancer-induced cognitive dysfunction has been made in
the 20 years since breast cancer patients first began
reporting the symptoms of ‘chemobrain’, the process of
determining how best to manage it remains a significant
challenge. There is a growing body of evidence that the
use of stimulants such as modafinil or methylphenidate
can help to improve cognitive measures in cancer pa-
tients with chemotherapy induced cognitive dysfunction
(Table 1). It would appear that modafinil is currently
favoured over methylphenidate because of its lesser side
effect profile and the associated stigma which methyl-
phenidate carries with it. The acetylcholinesterase in-
hibitor donepezil has also received attention due to its
role in slowing the cognitive decline seen in Alzheimer’s
Disease. However the results of using donepezil in can-
cer patients with cognitive dysfunction have been less
encouraging. The question of whether these agents can
provide any definite improvement in the lives of cancer
patients will require larger and more substantially pow-
ered trials before it can be fully answered.
A host of other agents are being studied in relation to
other neurocognitive diseases such as dementia, but
these again remain to be fully evaluated in cancer pa-
tients. The role of NSAIDs in preventing cognitive
decline is being questioned due to poor performance
in randomised controlled trials. Other compounds, in-
cluding N-acetylcysteine, resveratrol, and lithium, have
shown good initial performance in cell culture, animal
models, and some pilot studies, but remain to be fully
explored in appropriately designed clinical trials.
Table 1 A summary of the evidence regarding the potential benefit of pharmacologic intervention in cancer patients
with cognitive impairment and fatigue
Medication Mechanism of action Evidence of impact on cognition in cancer patients
MODAFINIL Thought to inhibit GABA outflow tracts within the
ventro-lateral preoptic area of the hypothalamus.
Clinical trials have looked at fatigue as a primary outcome and
cognition as a secondary one, although most have demonstrated
efficacy in improving cognition.
METHYLPHENIDATE Dopaminergic and noradrenergic agonist which acts to
increase levels of these neurotransmitters within the frontal
striatal network.
Randomised, double-blind trials in childhood cancer patients
suggest efficacy, but no evidence of superiority over placebo in
adult trials.
DONEPEZIL Centrally acting anticholinergic used in the management of
Alzheimer’s Disease.
Open-label Phase II studies in glioma patients suggested
statistically significant improvement in cognitive functioning.
LITHIUM Cation with an unknown mechanism of action used in the
management of bipolar mood disorder.
Murine models and efficacy data from bipolar patients suggest
anti-apoptotic and neuroprotective potential.
PPARs Nuclear hormone receptor functioning as a transcription
factor, targeted in the control of type II diabetes mellitus.
Murine models have demonstrated protection against radiation
induced cognitive dysfunction.
ARBs Antagonism of the angiotensin II receptor used in the
management of hypertension.
Murine models have demonstrated protection against radiation
induced cognitive dysfunction.
NOS Produces NO which functions as a neurotransmitter. None, theoretical benefit through induction of NOS and
subsequent antioxidant activities.
MEMANTINE NMDA antagonist used in the management of
Alzheimer’s Disease.
Recent randomised placebo-controlled double-blind trial in
patients receiving whole brain radiation showed longer time to
cognitive decline over placebo.
N-ACETYL
CYSTEINE
Provides cysteine, the rate limiting step in the synthesis of
the anti-oxidant glutathione.
Limited evidence of efficacy in Phase II trials in Alzheimer’s
patients.
RESVERATROL Unknown, demonstrates anti-apoptotic and anti-oxidant
properties within cell cultures.
Phase II studies in Alzheimer’s patients suggest little to no
cognitive benefit.
NSAIDS Inhibition of COX isoforms. Recent Cochrane review indicates no significant impact in slowing
cognitive decline in Alzheimer’s patients, Women’s Health study
subanalysis echoes this finding.
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The role of neuroprotective agents in cancer-induced
cognitive dysfunction is becoming clearer but still re-
mains to be fully defined. As more is learned about the
processes that contribute to cognitive decline in these
patients further opportunities to target these changes
with neuroprotective agents will become available. How-
ever the compounds currently being explored within the
literature need to be further evaluated before concrete
clinical recommendations can be made.
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